Hepatocyte growth factor as potential cardiovascular therapy.
about
PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional studyPhase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy.Treatment of avascular necrosis of the femoral head by hepatocyte growth factor-transgenic bone marrow stromal stem cells.The secretion pattern of perivascular fat cells is different from that of subcutaneous and visceral fat cells.
P2860
Hepatocyte growth factor as potential cardiovascular therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Hepatocyte growth factor as potential cardiovascular therapy.
@ast
Hepatocyte growth factor as potential cardiovascular therapy.
@en
type
label
Hepatocyte growth factor as potential cardiovascular therapy.
@ast
Hepatocyte growth factor as potential cardiovascular therapy.
@en
prefLabel
Hepatocyte growth factor as potential cardiovascular therapy.
@ast
Hepatocyte growth factor as potential cardiovascular therapy.
@en
P2093
P2860
P356
P1476
Hepatocyte growth factor as potential cardiovascular therapy.
@en
P2093
Ryuichi Morishita
Toshio Ogihara
Yasufumi Kaneda
P2860
P304
P356
10.1586/14779072.3.3.513
P577
2005-05-01T00:00:00Z